STOCK TITAN

Sinovac Biotech, Ltd. - SVA STOCK NEWS

Welcome to our dedicated news page for Sinovac Biotech, Ltd. (Ticker: SVA), a resource for investors and traders seeking the latest updates and insights on Sinovac Biotech, Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sinovac Biotech, Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sinovac Biotech, Ltd.'s position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Sinovac Biotech, Ltd.

Nasdaq:SVA

SVA Rankings

SVA Stock Data

642.44M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Beijing

About SVA

sinovac biotech ltd. is a china-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis a and b, seasonal influenza, h5n1 pandemic influenza (avian flu), h1n1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. in 2009, sinovac was the first company worldwide to receive approval for its h1n1 influenza vaccine, panflu.1, and has manufactured it for the chinese central government, pursuant to the government-stockpiling program. the company is also the only supplier of the h5n1 pandemic influenza vaccine to the government-stockpiling program. sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), of which the ev71 vaccine is currently in phase iii clinical trials, pneumococcal conjugate, pneumococcal polysaccharides, and rubella. sinovac sells its vaccine